Danaher (DHR) Rating Reiterated by Stifel Nicolaus

Danaher (NYSE:DHR)‘s stock had its “buy” rating restated by equities research analysts at Stifel Nicolaus in a report issued on Friday, January 19th. They presently have a $110.00 price target on the conglomerate’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 14.46% from the stock’s previous close.

Several other analysts also recently weighed in on DHR. Goldman Sachs Group reissued a “neutral” rating and issued a $83.00 price target on shares of Danaher in a research note on Tuesday, September 26th. Cowen restated a “buy” rating and issued a $90.00 price objective on shares of Danaher in a report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective on the stock in a report on Thursday, October 5th. Morgan Stanley restated an “overweight” rating and issued a $95.00 price objective (up previously from $86.00) on shares of Danaher in a report on Friday, October 6th. Finally, Credit Suisse Group upped their price objective on shares of Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Danaher currently has an average rating of “Buy” and a consensus target price of $100.13.

Danaher (NYSE:DHR) traded up $1.12 during trading on Friday, reaching $96.10. 1,504,893 shares of the company were exchanged, compared to its average volume of 2,930,000. Danaher has a fifty-two week low of $78.97 and a fifty-two week high of $104.82. The stock has a market cap of $66,850.00, a price-to-earnings ratio of 27.46, a price-to-earnings-growth ratio of 2.01 and a beta of 1.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.03. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $4.97 billion. Danaher had a net margin of 13.60% and a return on equity of 11.36%. Danaher’s revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.05 EPS. equities research analysts anticipate that Danaher will post 4.37 earnings per share for the current fiscal year.

In other Danaher news, CFO Daniel L. Comas sold 62,989 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $101.96, for a total value of $6,422,358.44. Following the transaction, the chief financial officer now directly owns 227,805 shares in the company, valued at $23,226,997.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 274,913 shares of company stock worth $27,729,293. 12.20% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Point72 Asset Management L.P. lifted its position in shares of Danaher by 276.8% during the third quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock worth $225,332,000 after purchasing an additional 1,929,751 shares in the last quarter. BlackRock Inc. lifted its position in shares of Danaher by 4.6% during the 4th quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock worth $3,804,169,000 after buying an additional 1,789,474 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Danaher by 16,410.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after buying an additional 1,476,901 shares during the period. Findlay Park Partners LLP lifted its position in shares of Danaher by 52.9% during the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after buying an additional 1,425,000 shares during the period. Finally, Koch Industries Inc. lifted its position in shares of Danaher by 29,127.3% during the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after buying an additional 1,399,859 shares during the period. Institutional investors and hedge funds own 75.88% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Danaher (DHR) Rating Reiterated by Stifel Nicolaus” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/danaher-dhr-stock-rating-reaffirmed-by-stifel-nicolaus-2.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply